Genen­tech parts ways with Re­lay Ther­a­peu­tics on SHP2 af­ter oth­er phar­ma ex­its

Roche’s Genen­tech is scrap­ping a col­lab­o­ra­tion and li­cense agree­ment with Re­lay Ther­a­peu­tics sur­round­ing the biotech’s clin­i­cal-stage oral SHP2 in­hibitor.

It’s the lat­est phar­ma­ceu­ti­cal com­pa­ny to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER